CYP2C9 Gene Polymorphism and Warfarin Dosage in Thrombotic Events Study Form in Northwest of Iran

Arterial and venous thrombosis is a common cardiovascular problem. Genetic background could influence the frequency and severity of vascular thrombosis and its response to therapy. Polymorphisms of two genes CYP2C9 and VKORC1, are identified as main genetic factors that influence warfarin dosage requirements. Peripheral blood samples were obtained from 200 patients who were hospitalized for different cardiovascular disorders. After DNA extraction, RFLP-PCR technique was used to determine the polymorphism of CYP2C9 gene in collected DNA samples. With using of Hardy-Weinberg Equilibrium, expected genotype frequencies of *1/*1,*1/*2, *1/*3, *2/*2,*2/*3 and *3/*3 in the CYP2C9 gene in collected were 72.6, 13.2, 11.3, 0.94, 1.88 and 0 percent in females and 64.8, 20.2, 12.7, 1.06, 0.94 and 0 percent in males respectively. The changes of allelic frequency in this study were not significantly different in females and males (p>0.05) the frequency of *2/*1 genotype was more prevalence in males than females (p<0.05). In this study, the main aim was determine the frequency of CYP2C9 gene in high risk group of patient that may experience the thrombotic events.